only approximate real-life clinical practice; however, the carefully constructed model and selection of input parameters, combined with data based directly on a post-hoc analysis of a clinical trial, makes this a useful contribution to the debate regarding the incremental benefit of intensive statin therapy.

PCV13

FINANCIAL ASSESSMENT OF A COMPREHENSIVE CARDIAC CARE PROGRAM FOR PATIENTS WITH OCCULSIVE CORONARY ARTERY DISEASE

Duda T1, Olson K1, Rasmussen J2, Hitzka K3, Sandahl B4, Hornik R5, Merlinchik J6
1Kaiser Permanent Colorado, Aurora, CO, USA, 2Kaiser Permanent Colorado, aurora, CO, USA

OBJECTIVES: To assess the financial impact of a comprehensive cardiac care (CCC) program on total health care expenditures after an initial coronary event. METHOD/Ds: This was a matched, retrospective analysis of a nurse- and pharmacist-managed CCC program that was designed to provide evidence-based lifestyle and medication support at the earliest opportunity after a coronary event. Patients with an incident occlusive CAD event between January 1999 and June 2004 were categorized into intervention and comparator groups, respectively, by enrollment or never enrollment (No CCC) into the CCC. Patients were matched 1:1 on chronic disease score (CDS) and 180-day pre-coronary event (baseline) total health care expenditures. Pharmacy and medical utilization events were extracted from electronic administrative and claims databases. Utilization events were collected after the initial coronary event until death, health plan termination, three years, or December 31, 2005, whichever came first (follow-up). Expenditures were adjusted by the Kaiser Permanente Division Decision Support System for (1) dollars) to application events. An intervention cost of $1 follow-up-day was applied to all CCC patients. Expenditures/day were modeled with adjustment for matching variables, patient characteristics, baseline expenditures, and intra- coronary event related costs and patients. RESULTS: A total of 628 CCC patients were matched to 628 NO CCC patients. Patients in the No CCC group were slightly older, more likely to be female, and to have had a myocardial infarction. Mean/median baseline expenditures and CDS were equivalent. During follow-up, 12 and 98 cardiac-related deaths occurred in mean/median total health care expenditures/day were $775/10 and $1595/45 for the CCC and No CCC groups, respectively (both $p < 0.001). After adjustment, CCC patients were associated with a $103/day lower total health care expenditures ($0.01; adjusted R-square = 0.71 with log-transformed expenditures). CONCLUSIONS: Comprehensive and aggressive implementation of secondary cardiac prevention strategies with close monitoring and follow-up of CAD patients is associated with reduced health care expenditures.

PCV15

PHARMAECONOMIC MODEL OF ENOXAPARIN VERSUS HEPARIN FOR PREVENTION OF VENOUS THROMBOEMBOLISM IN MEDICAL PATIENTS

Vieis P1, Follador W2, Gonçalves J1, De Sera V1
1São Paulo University, São Paulo, São Paulo, Brazil, 2Santo-Inês, São Paulo, São Paulo, Brazil

OBJECTIVES: Venous thromboembolism (VTE) causes significant morbidity and mortality and represents a huge health economic burden. Although enoxaparin has some advantages over unfractionated heparin (UFH), both are recommended for prophylaxis of VTE according to the guidelines from the Brazilian Medical Association. We present a tool to aid in selecting among similarly effective agent for VTE prophylaxis. The costs of UFH and enoxaparin to prevent venous thromboembolism in medical patients in the Brazilian treatment environment were compared. METHODS: A Markov model was used in a pharmaeconomic comparison of enoxaparin and UFH, each given for seven days, for the prophylaxis of VTE in medical patients. In the model four main outcome pathways could follow prophylaxis: major bleeding, proximal deep venous thrombosis (without or with pulmonary embolism), distal deep venous thrombosis (DVT), and no DVT. False-negative or false-positive clinical diagnosis of VTE were also taken into account. Probabilities of thromboembolic events and major bleeding were derived from published randomized clinical trials and meta-analysis. Costs were calculated using the micromax costing technique and the administrative health care claims database of a major Brazilian Health Maintenance Organization from July, 2007 to June, 2008. The claims represented a full range of health plans levels at different hospitals. Only the costs related to the VTE prophylaxis and adverse events, acute VTE diagnosis, treatment and complications were considered. RESULTS: Enoxaparin dominated UFH. There were cost savings of $4.124 Brazilian reais per patient. 1,000 patients by using enoxaparin instead of UFH for prophylaxis of VTE. The base-case analysis also demonstrated that the extra costs in the UFH group were mainly related to the management of hemorrhagic adverse events. CONCLUSION/S: This model of enoxaparin versus UFH for VTE prophylaxis in medical patients showed that enoxaparin was less costly than UFH in overall expected costs from the hospital perspective.

PCV16

THE IMPACT OF A STATIN FORMULARY CHANGE ON HEALTH OUTCOMES AND MEDICAL COSTS

Vieira AO, Cox E

OBJECTIVES: To determine the effect of a formulary change in the statin drug class on health outcomes and disease-specific health care costs. METHODS: A retrospective cohort design was implemented using pharmacy and medical claims data from a large national employer group. Patients (n = 330) with one or more claims for atorvastatin or another statin during the six months prior to a formulary change on January 1, 2006 were identified and evaluated. The formulary change was implemented for all patients however, only those patients taking atorvastatin were affected. Cardiac-related medical events (tests, doctor visits, outpatient facility visits, and acute cardiovascular events) and disease-specific costs during the year following the formulary change were measured. The impact of formulary change on cardiac-related medical events and disease-specific costs were evaluated using multivariate analysis controlling for gender, age, comorbidity status, and drug indication (primary vs. secondary prevention). RESULTS: Of the 330 patients, 180 (55%) used atorvastatin prior to the formulary change. After the implementation of the formulary change, 146 (81%) of patients switched to a preferred statin drug, 19 (10%) discontinued statin therapy, and 16 (9%) continued taking atorvastatin as a non-preferred drug. There were no significant differences in the proportions of patients with cardiac tests (p = 0.70), doctor’s visits (p = 0.64), outpatient facility visits (p = 0.52), or acute cardiovascular events (p = 0.13) in the year after the formulary change between patients with pre-formulary change claims for atorvastatin or another statin. There were no statistically significant differences in health care costs among patients with pre-formulary change claims for atorvastatin or another statin after adjustment for covariates (OR = 0.89, 95% CI 0.41-1.92). CONCLUSIONS: Changing the formulary status of atorvastatin does not appear to adversely affect the total medical costs or utilization of cardiac-related health care services.

PCV17

ECONOMIC IMPACT OF EDARAVONE THERAPY FOR PATIENTS WITH LACUNAR INFARCTION IN JAPAN

Inoue S1, Okuda S2, Yamaguchi Y1
1Creon Research and Consulting Inc, Shibuya-tu, Tokyo, Japan, 2National Hospital Organization Nagoya Medical Center, Nagoya, Aichi, Japan, 3National Cardiovascular Center, Osaka, Japan

OBJECTIVES: Edaravone (Radicut4), which was first approved in Japan in 2001 as a free radical scavenger, is widely used for the treatment of acute ischemic stroke in Japan. The purpose of this study was to estimate the economic impact of edaravone therapy for patients with lacunar infarction. METHODS: Japanese patients with lacunar infarction aged 35 years or older were included in this analysis. We compared the economic impact of treatment for lacunar infarction between the edaravone group (E group) and the non-edaravone group (NE group). For the basic information on patients for this analysis, we used previously published meta-analysis data on the modified Rankin Scale (mRS) distribution 1 month or more after the occurrence of lacunar infarction. Four types of costs were considered: hospitalization costs for lacunar infarction treatment, nursing-care costs after hospital discharge, and prescription costs for edaravone and hospitalization and due to work loss. RESULTS: The total costs per patient with lacunar infarction in the E and non-E groups were US$42,054 (1US $ = 92 JPY) and US$47,270, respectively, and the potential cost savings for using edaravone therapy was estimated at US$5,216. The breakdown of total costs in the E and non-E groups, respectively were for hospitalization costs: US$10,215 (24.3%), and US$15,130 (17.2%), nursing-care costs: US$14,779 (35.1%), and US$18,256 (38.6%), decreased productivity costs due to hospitalization: US$1,956 (4.7%), and US$2,065 (4.4%), and those due to work loss: US$15,105 (35.9%), and US$8,491 (39.5%). CONCLUSION: In this analysis, edaravone therapy for patients with lacunar infarction was ultimately a promising cost saving therapy compared with other therapies that did not use edaravone, as it avoided nursing-care costs and productivity loss despite being more expensive during acute treatment.

PCV18

COST-EFFECTIVENESS OF RIVAROXABAN VERSUS ENOXAPARIN ON PHRYPHALYSIS AFTER TOTAL HIP OR TOTAL KNEE REPLACEMENT IN KOREA

Kim J1, Pollock R2, Jung S3, Diamantopoulous A4, Lee M5
1IM Health, Seoul, South Korea, 2IM Health, Basel, Switzerland, 3Bayer Korea, Seoul, South Korea, 4Bayer Health, London, UK, 5Bayer HealthCare, Ulsan, Korea, UK

OBJECTIVES: To assess the cost-effectiveness of oral rivaroxaban versus subcutaneous enoxaparin for prevention of venous thromboembolism (VTE) following total hip or total knee replacement (THR or TKR) in Korea. METHODS: An economic model was developed to evaluate the clinical and economic consequences of rivaroxaban versus enoxaparin, based on the RECORD2 and 3 randomized controlled trials. RECORD2 compared a 35-day course of rivaroxaban with a 12-day course of enoxaparin in THR, while RECORD3 compared 12-day courses of rivaroxaban and enoxaparin following TKR. In RECORD2, rivaroxaban reduced total VTE (composite of any deep vein thrombosis, non-fatal pulmonary embolism, and all-cause mortality) by 79% and symptomatic VTE by 80% versus 12-day enoxaparin. In RECORD3, rivaroxaban reduced total VTE by 49% and symptomatic VTE by 66% versus enoxaparin. Occurrence of major bleeding was similar with both agents. The model accounted resource use according to primary research data and included direct medical costs from the Korean Health Insurance Review Agency. Utilities were derived from published literature and clinical and economic outcomes were discounted at a 5% annual rate in line with Korean guidelines. The model reported effectiveness outcomes in quality-adjusted life years (QALYs) and costs in Korean Won (KRW) and was run over a five-year time horizon. RESULTS: In THR, rivaroxaban demonstrated preferrential patient cost savings of KRW 40,803 versus enoxaparin and a gain of 0.0027 QALYs per patient. In TKR, rivaroxaban reduced per-patient costs by KRW 27,692 and resulted in a gain of 0.0019 QALYs per patient. Cost savings in the rivaroxaban arm